Cargando…
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
Despite recent advances in ovarian cancer (OC) treatment, including the introduction of bevacizumab and PARP-inhibitors, OC remains a lethal disease. Other therapeutic options are being explored, such as immunotherapy (IT), which has been proved effective in many solid tumors. Findings about tumor-i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806340/ https://www.ncbi.nlm.nih.gov/pubmed/36601114 http://dx.doi.org/10.3389/fimmu.2022.1094017 |
_version_ | 1784862516243857408 |
---|---|
author | Provinciali, Nicoletta Greppi, Marco Pesce, Silvia Rutigliani, Mariangela Briata, Irene Maria Buttiron Webber, Tania Fava, Marianna DeCensi, Andrea Marcenaro, Emanuela |
author_facet | Provinciali, Nicoletta Greppi, Marco Pesce, Silvia Rutigliani, Mariangela Briata, Irene Maria Buttiron Webber, Tania Fava, Marianna DeCensi, Andrea Marcenaro, Emanuela |
author_sort | Provinciali, Nicoletta |
collection | PubMed |
description | Despite recent advances in ovarian cancer (OC) treatment, including the introduction of bevacizumab and PARP-inhibitors, OC remains a lethal disease. Other therapeutic options are being explored, such as immunotherapy (IT), which has been proved effective in many solid tumors. Findings about tumor-infiltrating cytotoxic and regulatory T cells, together with the expression of PD-1 on immune cells and of PD-L1 on tumor cells, gave the rationale for an attempt to the use of IT also in OC. We treated two patients with avelumab, an anti-PD-L1 monoclonal antibody, after the first line of chemotherapy: Patient A underwent 19 cycles of maintenance therapy with avelumab with a disease-free interval of 12 months, whereas patient B showed a slight progression of disease after only eight cycles. A higher PD-L1 expression in tumor cells of patient A was detected. She also underwent a genomic assessment that described the presence of a high Tumor Mutational Burden (TMB) and a status of Loss of Heterozygosity (LoH). This different response to the same treatment puts in evidence that some genomic and immune features might be investigated. |
format | Online Article Text |
id | pubmed-9806340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98063402023-01-03 Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art Provinciali, Nicoletta Greppi, Marco Pesce, Silvia Rutigliani, Mariangela Briata, Irene Maria Buttiron Webber, Tania Fava, Marianna DeCensi, Andrea Marcenaro, Emanuela Front Immunol Immunology Despite recent advances in ovarian cancer (OC) treatment, including the introduction of bevacizumab and PARP-inhibitors, OC remains a lethal disease. Other therapeutic options are being explored, such as immunotherapy (IT), which has been proved effective in many solid tumors. Findings about tumor-infiltrating cytotoxic and regulatory T cells, together with the expression of PD-1 on immune cells and of PD-L1 on tumor cells, gave the rationale for an attempt to the use of IT also in OC. We treated two patients with avelumab, an anti-PD-L1 monoclonal antibody, after the first line of chemotherapy: Patient A underwent 19 cycles of maintenance therapy with avelumab with a disease-free interval of 12 months, whereas patient B showed a slight progression of disease after only eight cycles. A higher PD-L1 expression in tumor cells of patient A was detected. She also underwent a genomic assessment that described the presence of a high Tumor Mutational Burden (TMB) and a status of Loss of Heterozygosity (LoH). This different response to the same treatment puts in evidence that some genomic and immune features might be investigated. Frontiers Media S.A. 2022-12-19 /pmc/articles/PMC9806340/ /pubmed/36601114 http://dx.doi.org/10.3389/fimmu.2022.1094017 Text en Copyright © 2022 Provinciali, Greppi, Pesce, Rutigliani, Briata, Buttiron Webber, Fava, DeCensi and Marcenaro https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Provinciali, Nicoletta Greppi, Marco Pesce, Silvia Rutigliani, Mariangela Briata, Irene Maria Buttiron Webber, Tania Fava, Marianna DeCensi, Andrea Marcenaro, Emanuela Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art |
title | Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art |
title_full | Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art |
title_fullStr | Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art |
title_full_unstemmed | Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art |
title_short | Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art |
title_sort | case report: variable response to immunotherapy in ovarian cancer: our experience within the current state of the art |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806340/ https://www.ncbi.nlm.nih.gov/pubmed/36601114 http://dx.doi.org/10.3389/fimmu.2022.1094017 |
work_keys_str_mv | AT provincialinicoletta casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT greppimarco casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT pescesilvia casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT rutiglianimariangela casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT briatairenemaria casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT buttironwebbertania casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT favamarianna casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT decensiandrea casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart AT marcenaroemanuela casereportvariableresponsetoimmunotherapyinovariancancerourexperiencewithinthecurrentstateoftheart |